Clinical Trials | November 21, 2025
_256_384.png)
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
